| Abstrakt: |
A report from Jagiellonian University College of Medicine in Krakow, Poland, provides new insights into antidiabetic agents, specifically focusing on the drug rosiglitazone. Rosiglitazone is used in the treatment of type 2 diabetes and is primarily metabolized by the enzyme cytochrome P450 (CYP) 2C8. The researchers developed a physiologically based pharmacokinetic (PBPK) model for rosiglitazone to predict potential drug-drug interactions and changes in metabolite exposure. The model was verified and showed good predictive performance. This research was supported by the Ministry of Science and Higher Education, Poland, and Ryvu Therapeutics, Poland. [Extracted from the article] |
